BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rhucin: SPA received

Pharming received an SPA from FDA after amending the protocol for an ongoing, double-blind, placebo-controlled Phase III trial evaluating IV Rhucin. In May, Pharming amended the trial to increase enrollment to about 75 from 50 patients and to modify the manner in which the primary endpoint is assessed to address...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >